Autologous Dendritic Cell / Tumor Antigen (ADCTA-SSI-G1) for Adjuvant Immunotherapy in Standard Treatment of Recurrent Glioblastoma Multiforme (GBM): A Multi-center, Open-label, Randomized Phase III Clinical Trial
To confirm the result of previous Phase I/II and phase II clinical trials, this trial is to test the efficacy and safety of ADCTA immunotherapy plus the standard therapy in comparison with standard therapy alone in patients with recurrent GBM.
100 Clinical Results associated with Safe Save Medical Cell Sciences & Technology Co., Ltd.
0 Patents (Medical) associated with Safe Save Medical Cell Sciences & Technology Co., Ltd.
100 Deals associated with Safe Save Medical Cell Sciences & Technology Co., Ltd.
100 Translational Medicine associated with Safe Save Medical Cell Sciences & Technology Co., Ltd.